202
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Evaluating quantity and quality of literature focusing on health economics and pharmacoeconomics in Gulf Cooperation Council countries

, , &
Pages 403-414 | Received 13 Mar 2018, Accepted 17 May 2018, Published online: 30 May 2018

References

  • Newhouse JP Reimbursing health plans and health providers: efficiency in production versus selection. J Econ Lit. 1996; 34(3): 1236–1263
  • Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ. 1997; 6: 217–227.
  • Cutler DM, Reber S Paying for health insurance: the trade-off between competition and adverse selection. Q J Econ. 1998; 113: 433–466.
  • Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: university press; 2005.
  • Adams ME, McCall NT, Gray DT, et al. Economic analysis in randomized control trials. Med Care. 1992;30(3):231–243.
  • Udvarhelyi IS, Colditz GA, Rai A, et al. Cost-effectiveness and cost-benefit analyses in the medical literature. Ann Intern Med. 1992;116(3):238–244.
  • Gerard K Cost-utility in practice: a policy maker’s guide to the state of the art. Health Policy. 1992;21(3):249–279.
  • Al-Aqeel SA State of health economic evaluation research in Saudi Arabia: a review. Clinicoecon Outcomes Res. 2012;4:177–184.
  • The Cooperation Council. The Arab States of the Gulf. [cited 2017 Jun 30]; Available from http://www.gcc-sg.org/en-us/AboutGCC/Pages/Primarylaw.aspx
  • Howard JJ Medical devices and the Middle East: market, regulation, and reimbursement in Gulf Cooperation Council states. Med Devices (Auckl). 2014;7;385–395.
  • Moher D, Liberati A, Tetzlaff J, et al. The PRISMA Group preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6(6):16.
  • Oderda GM The importance of perspective in pharmacoeconomic analyses. J Pain Palliat Care Pharmacother. 2002;16(4):65–69.
  • Ofman JJ, Sullivan SD, Neumann PJ, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm. 2003;9(1):53–61.
  • Baraka A, Juma T, Asfar SK, et al. Conserving blood in preparation for elective surgery. J R Soc Med. 1991;84(10):600–601.
  • Al-Umran K Neonatal hip instability in Saudi Arabia: results and cost effectiveness. Ann Saudi Med. 1994;14(1):16–18.
  • Al-Dawood KM Non-fatal occupational injuries admitted to hospitals among general organization for social insurance workers in Al-Khobar city, Saudi Arabia: experience of one year. J Family Community Med. 2000;7(2):35.
  • Abou-Auda HS. An economic assessment of the extent of medication use and wastage among families in Saudi Arabia and Arabian Gulf countries. Clin Ther. 2003;25(4):1276–1292.
  • Al-Zakwani I, Hanssens Y, Deleu D, et al. Annual direct medical cost and contributing factors to total cost of epilepsy in Oman. Seizure. 2003;12(8):555–560.
  • Al Khabori M, Kumar S, Khandekar R. Magnitude of impacted earwax in Oman, its impact on hearing impairment and economic burden of earwax on health services. Indian J Med Sci. 2007;61(5):278–285.
  • Al-Siyabi K, Al-Riyami K. Value and types of medicines returned by patients to Sultan Qaboos University Hospital Pharmacy, Oman. Sultan Qaboos Univ Med J. 2007;7(2):109–115.
  • Al Awaidy SA, Bawikar S, Al Busaidy S, et al. Considerations for introduction of a rotavirus vaccine in Oman: rotavirus disease and economic burden. J Infect Dis. 2009;200 Suppl 1:S248–S53.
  • El Shafie K, Al-Shaqsi A, Al-Mahrouqi B, et al. The diagnostic yield of thyroid function tests and their cost-effectiveness in the student clinic at Sultan Qaboos University: retrospective chart review. Sultan Qaboos Univ Med J. 2010;10(2):215.
  • Alsultan MS, Mayet AY, Malhani AA, et al. Pattern of intravenous proton pump inhibitors use in ICU and non-ICU setting: a prospective observational study. Saudi J Gastroenterology.2010;16(4):275.
  • Al-Maskari F, El-Sadig M, Nagelkerke N. Assessment of the direct medical costs of diabetes mellitus and its complications in the United Arab Emirates. BMC Public Health. 2010;10(1):679.
  • Khoury H, Ogilvie I, El Khoury AC, et al. Burden of rotavirus gastroenteritis in the Middle Eastern and North African pediatric population. BMC Infect Dis. 2011;11:9.
  • Al Saran K, Sabry A The cost of hemodialysis in a large hemodialysis center. Saudi J of Kidney Dis Transpl. 2012;23(1):78.
  • Khaliq AA The Saudi health care system: a view from the minaret. World Health Popul. 2012;13(3):52–64.
  • Alameddine M, Nassir A The influence of urine cytology on our practice. Urol Ann. 2012;4(2):80.
  • Howidi M, Al Kaabi N, El Khoury AC, et al. Burden of acute gastroenteritis among children younger than 5 years of age–a survey among parents in the United Arab Emirates. BMC Pediatr. 2012;12(1):74.
  • Tuma MA, Acerra JR, El-Menyar A, et al. Epidemiology of workplace-related fall from height and cost of trauma care in Qatar. Int J Crit Illn Inj Sci. 2013;3(1):3–7.
  • Alhowaish AK. Economic costs of diabetes in Saudi Arabia. J Family Community Med. 2013;20(1):1–7
  • Al-Busaidi NH, Habibullah Z, Soriano JB. The asthma cost in Oman. Sultan Qaboos Univ Medl J. 2013;13(2):218.
  • Khan SY, Al-Balushi ZN, Bhatti KM, et al. Cost comparison between laparoscopic and open appendectomies in children. Sultan Qaboos Univ Med J. 2013;13(2):275.
  • Algahtani F, Al Aseri Z, AlDiab A, et al. Hospital versus home treatment of deep vein thrombosis in a tertiary care hospital in Saudi Arabia: are we ready? Saudi Pharm J. 2013;21(2):165–168.
  • Alkhamis A, Hassan A, Cosgrove P Financing healthcare in Gulf Cooperation Council countries: a focus on Saudi Arabia. Int J Health Plann Manage. 2014;29(1):e64–e82.
  • Bawazeer AM, Joharjy HI. The association of human leukocyte antigen B27 with anterior uveitis in patients from the western region of Saudi Arabia: a retrospective study. Clin Ophthalmol. 2013;7:2107–2111.
  • Ahmad S, Khan Z, Hagen F, et al. Simple, low-cost molecular assays for TR34/L98H mutations in cyp51A gene for rapid detection of triazole-resistant Aspergillus fumigatus isolates. J Clin Microbiol. 2014;52(6)2223–2227.
  • Al Awaidy ST, Gebremeskel BG, Al Obeidani I, et al. Cost effectiveness of a pentavalent rotavirus vaccine in Oman. BMC Infect Dis. 2014;14:334.
  • Al Balushi K, Al-Shibli S, Al-Zakwani I Drug utilization patterns in the emergency department: a retrospective study. J Basic Clin Pharm. 2013;5(1):1–6.
  • Mihaljevic T, Koprivanac M, Kelava M, et al. Value of robotically assisted surgery for mitral valve disease. JAMA Surg. 2014;149(7):679–686.
  • Al-Qadhi W, Ur Rahman S, Ferwana MS, et al. Adult depression screening in Saudi primary care: prevalence, instrument and cost. BMc Psychiatry. 2014;14:190.
  • Alzaabi A, Alseiari M, Mahboub B Economic burden of asthma in Abu Dhabi: a retrospective study. Clinicoecon Outcomes Res. 2014;6:445–450
  • Hamidi S Health services financing and delivery: analysis of policy options for Dubai, United Arab Emirates. Clinicoecon Outcomes Res. 2015;7:133–143
  • Joosub I, Gray A, Crisostomo A, et al. Cost-minimization analysis of imipenem/cilastatin versus meropenem in moderate to severe infections at a tertiary care hospital in Saudi Arabia. Saudi Pharm J. 2015;23(6):626–634.
  • Al-Kaabi SK, Atherton A Impact of noncommunicable diseases in the State of Qatar. Clinicoecon Outcomes Res. 2015;7:377–385.
  • Al Alawi S, Abdulkarim S, Elhennawy H, et al. Outpatient parenteral antimicrobial therapy with ceftriaxone for acute tonsillopharyngitis: efficacy, patient satisfaction, cost effectiveness, and safety. Infect Drug Resist. 2015;8:279–285
  • Nasef SA, Shaaban AA, Mould-Quevedo J, et al. The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors in the treatment of osteoarthritis in Saudi Arabia. Health Econ Rev. 2015;5(1):53.
  • Al-Badriyeh D, Fahey M, Alabbadi I, et al. Statin selection in Qatar based on multi-indication pharmacotherapeutic multi-criteria scoring model, and clinician preference. Clin Ther. 2015;37(12):2798–2810.
  • Ahmad AS, Mudasser S, Khan MN, et al. Outcomes of cardiopulmonary resuscitation and estimation of healthcare costs in potential ‘Do not resuscitate’ cases. Sultan Qaboos Univ Med J. 2016;16(1):e27–e34.
  • Hamidi S, Abouallaban Y, Alhamad S, et al. Patient cost-sharing for ambulatory neuropsychiatric services in Abu Dhabi, UAE. Int J Ment Health Syst. 2016;10:34.
  • Al-Ahmad M, Alowayesh MS, Carroll NV Economic burden of refractory chronic spontaneous urticaria on Kuwait’s health system. Clinicoecon Outcomes Res. 2016;8:163–169.
  • Al-Badriyeh D, Alabbadi I, Fahey M, et al. Multi-indication pharmacotherapeutic multicriteria decision analytic model for the comparative formulary inclusion of proton pump inhibitors in Qatar. Clin Ther. 2016;38(5):1158–1173.
  • Maraiki F, Farooq F, Ahmed M Eliminating the use of intravenous glass bottles using a FOCUS‐PDCA model and providing a practical stability reference guide. Int J Pharm Pract. 2016;24(4):271–282.
  • Bener A, Al-Hamaq A Predictions burden of diabetes and economics cost: contributing risk factors of changing disease prevalence and its pandemic impact to Qatar. Exp Clin Endocrinol Diabetes. 2016;124(8):504–511.
  • Islam SS, Abru AF, Al Obaidani S, et al. Trends in CT request and related outcomes in a pediatric emergency department. Oman Med J. 2016;31(5):365–369.
  • Alawi MM, Darwesh BM A stepwise introduction of a successful antimicrobial stewardship program: experience from a tertiary care university hospital in Western, Saudi Arabia. Saudi Med J. 2016;37(12):1350–1358.
  • Salem K, ElKhateeb O. Gender‐adjusted and age‐adjusted economic inpatient burden of congestive heart failure: cost and disability‐adjusted life‐year analysis. ESC Heart Fail. 2017;4(3):259–265.
  • Al-Otaibi H, Al-Otaibi MD, Khandekar R, et al. Validity, usefulness and cost of RETeval system for diabetic retinopathy screening. Transl Vis Sci Technol. 2017;6(3):3.
  • Hindawi S, Badawi M, Fouda F, et al. Testing for HTLV 1 and HTLV 2 among blood donors in Western Saudi Arabia: prevalence and cost considerations. Transfus Med. 2018;(1):60–64 28
  • Schubert A, Buchholt AT, El Khoury AC, et al. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates. Curr Med Res Opin. 2017;33(6)1155–1163.
  • Al-Aidaroos AY, Standaert B, Meszaros K, et al. Economic assessment of rotavirus vaccination in Saudi Arabia. J Infect Public Health. 2017;10(5):564–571.
  • Alsaqa’aby M, Vaidya A, Khreis N, et al. Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia. J Ann Saudi Med. 2017; 37(6): 433–443.
  • Hjelmgren J, Berggren F, Andersson F Health economic guidelines—similarities, differences and some implications. Value Health. 2001;4(3):225–250.
  • Australia CWO. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmacuetical Benefits Advisory Committee: including economic analyses. Canberra: Department of Health and Community Services. 1995.
  • Elixhauser A, Luce BR, Taylor WR, et al. Health care CBA/CEA: an update on the growth and composition of the literature. Med Care. 1993;31(7suppl): JS1–J149.
  • Assessment CCOfHT. Guidelines for economic evaluation of pharmaceuticals. Canada: Canadian Coordinating Office for Health Technology Assessment; 1997.
  • Lee KS, Brouwer WB, Lee SI, et al. Introducing economic evaluation as a policy tool in Korea: will decision makers get quality information? A critical review of published Korean economic evaluations. Pharmacoeconomics. 2005;23:(7):709–721.
  • Gavaza P, Rascati K, Brown C, et al. The state of health economic and pharmacoeconomic evaluation research in Zimbabwe: a review. Curr Ther Res Clin Exp. 2008;69(3):268–285.
  • Teerawattananon Y, Russell S, Mugford M A systematic review of economic evaluation literature in Thailand. Pharmacoeconomics. 2007;25(6):467–479.
  • Gavaza P, Rascati KL, Oladapo AO, et al. The state of health economic evaluation research in Nigeria. Pharmacoeconomics. 2010;28(7):539–553
  • Walker D, Fox-Rushby JA Economic evaluation of communicable disease interventions in developing countries: a critical review of the published literature. Health Econ. 2000;9:681–698.
  • Maynard A Developing the health care market. The Econ J. 1991;101(408):1277–1286.
  • Neumann PJ, Stone PW, Chapman RH, et al. The quality of reporting in published cost-utility analyses, 1976–1997. Ann Intern Med. 2000;132(12):964–972.
  • Gerard K, Smoker I, Seymour J. Raising the quality of cost-utility analyses: lessons learnt and still to learn. Health Policy. 1999;46(3):217–238.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.